New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
04:55 EDTPFE, PFE, VRTX, VRTX, BAYRY, BAYRY, CBST, CBST, IRWD, IRWD, AMGN, AMGN, SHPG, SHPG, GSK, GSK, CELG, CELG, BMY, BMY, LLY, LLYQ1 Productions to hold a conference
Customer Centric Medical Information Conference to be held in Boston on June 26-27.
News For PFE;BMY;CELG;GSK;SHPG;AMGN;IRWD;CBST;BAYRY;VRTX;LLY From The Last 14 Days
Check below for free stories on PFE;BMY;CELG;GSK;SHPG;AMGN;IRWD;CBST;BAYRY;VRTX;LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 13, 2014
16:19 EDTGSKOn The Fly: Closing Wrap
Subscribe for More Information
16:17 EDTAMGNAmgen issues voluntary recall of Aranesp prefilled syringes in several countries
Subscribe for More Information
16:09 EDTAMGNAmgen slips lower after hours, levels to watch
Subscribe for More Information
16:04 EDTAMGNAmgen says Phase 3 clinical trial FOCUS did not meet primary endpoint
Subscribe for More Information
14:45 EDTVRTXVertex volatility at record low
Subscribe for More Information
13:13 EDTGSKInterMune exploring sale after bids from Sanofi, Roche, Glaxo, Bloomberg says
InterMune (ITMN) is working with its financial advisers Goldman Sachs (GS) and Centerview Partners to evaluate takeover bids it has received from Sanofi (SNY), Roche (RHHBY), GlaxoSmithKline (GSK) and Actelion (ALIOF), said Bloomberg, citing people with knowledge of the matter. The report noted that one of the sources said Sanofi has so far shown the most interest in a deal for InterMune, whose shares are up more than 13% to $51.56 following the first headlines from the report. Reference Link
August 12, 2014
17:07 EDTPFEPfizer announces results from Lyrica studies conducted in China
Pfizer announced top-line results from two placebo-controlled studies conducted in China with Lyrica in patients with postherpetic neuralgia, pain after shingles or PHN, and painful diabetic peripheral neuropathy, pDPN, respectively.The PHN Phase 4 study, A0081276, met its primary endpoint by demonstrating a statistically significant reduction in pain when compared to placebo. Separately, the pDPN Phase 3 study, A0081265, did not meet its primary endpoint, a statistically significant change in endpoint mean pain score relative to placebo. The PHN study was an eight-week, randomized, double-blind, multi-center, placebo-controlled, post-marketing study evaluating the efficacy, safety and tolerability of pregabalin 300mg/day in the treatment of subjects with PHN. For the primary efficacy parameter, change from baseline in weekly mean pain scores, a significant treatment difference of -0.71 points for pregabalin relative to placebo was observed. The safety profile in this study was consistent with the known profile for Lyrica.
11:24 EDTSHPGOptions with increasing implied volatility
Subscribe for More Information
07:15 EDTGSKWHO says ethical to offer unproven interventions in light of Ebola outbreak
Subscribe for More Information
06:18 EDTGSKGSK CEO faces pressure as company deals with weak sales, allegations, WSJ says
Subscribe for More Information
August 11, 2014
12:57 EDTGSKGlaxoSmithKline facing new bribery allegations in Syria, Reuters reports
Subscribe for More Information
11:58 EDTLLYMannKind rallies after inking licensing agreement with Sanofi
Subscribe for More Information
08:47 EDTGSKGlaxo to conduct Ebola vaccine trials later this year, Guardian says
Subscribe for More Information
05:32 EDTBAYRYRegeneron Eylea injection receives EU approval for DME treatment
Subscribe for More Information
August 8, 2014
17:49 EDTCBSTCubist issues voluntary nationwide recall of nine lots of CUBICIN
Subscribe for More Information
10:36 EDTSHPGOptions with increasing implied volatility
Subscribe for More Information
10:03 EDTBMYBristol-Myers Hodgkin lymphoma treatment granted orphan drug status
Subscribe for More Information
09:03 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
06:39 EDTPFEPfizer faces torrent of Lipitor suits, Reuters says
Subscribe for More Information
06:18 EDTGSKRoyal Bank of Scotland's Hampton leads race to become new GSK chair, FT reports
Royal Bank of Scotland (RBS) Chairman Philip Hampton is the frontrunner to succeed Christopher Gent as chairman of GlaxoSmithKline (GSK), the Financial Times reports, citing sources. Gent will step down from his role at GSK next year. Hampton is not expected to step down from RBS until after May's general election, the sources say. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use